Cogstate is at the forefront of Alzheimer’s research via participation in several key longitudinal public private partnership (PPP) studies such as secondary prevention trials including A4 and DIAN, as well as registries and natural history studies including AIBL, ADNI, BHR, and the APT Webstudy.

Utilizing open data sets made available through our involvement in PPPs, Cogstate scientists can advise study teams on endpoint selection, powering decisions, and interpretation of study results supportive of product efficacy, safety, and differentiating claims.

A paper in Drug Discovery Today—co-authored by two Cogstate scientists—notes how cognitive data can be used for better Go/No-Go decision-making in Alzheimer’s clinical trials and explores how to apply robust decision-making criteria depending on the specific stage of development, mechanism of action, and design of the trial. Read more.

Cogstate managed the endpoint data quality program of all cognitive and clinical outcomes in a global phase 3 trial of an amyloid-lowering drug for patients with early Alzheimer’s disease. To ensure high fidelity measures, the large global trial required a rigorous rater qualification and training program enhanced by central review of ratings by Cogstate’s global network of expert neuropsychologist consultants and senior scientists. The US Food and Drug Administration (FDA) approved the launch of the treatment for marketing.

The Cogstate International Shopping List test (ISLT) was used to select appropriate patients for the global Phase 3 MissionAD studies investigating the BACE inhibitor elenbecestat. More than 8,000 adults were screened for entry, and the research team fully enrolled their trials. Data showed the ability of the ISLT to confirm a clinically important memory impairment. (Albala, et al, CTAD 2017) (YouTube Summary)

Cogstate digital assessments were used as exploratory efficacy endpoints in a Ph 2 study of PQ912 in Alzheimer’s disease. Data indicated a treatment-related improvement in working memory, helping guide the team into future study questions and considerations regarding the impact of PQ912. (Scheltens et al. Alzheimer’s Research & Therapy (2018) 10:107)

Cogstate sent a survey to 261 English speaking raters trained by Cogstate clinical expert coaches to administer complex Alzheimer’s assessments. 48 individuals responded and gave overwhelmingly positive reviews, with questions on coaches’ competency and feedback receiving 100% positive (Strongly Agree/Agree) responses. (Wacker, et al, AAIC 2022)

A large online registry targeting the assessment of Alzheimer’s disease utilized the Cogstate Brief Battery™. 75,491 participants completed independent, at-home tests every 3-6 months, resulting in extensive baseline (57,000) and longitudinal (28,000) data collection for the study team. Cogstate tests have high usability for the remote assessment of cognition. (Mackin et al. Alzheimers Dement 2018 Jun 21;10:573-582. Nosheny et al. Alzehimers Dement 2018 Oct 15;4:565-574. Weiner et al. Alzheimers Dement 2018 Aug;14(8):1063-1076)